Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression

被引:78
作者
Kyle, Robert A. [1 ]
Rajkumar, S. Vincent [1 ]
机构
[1] Mayo Clin, Div Hematol, Rochester, MN USA
关键词
monoclonal gammopathy of undetermined significance; multiple myeloma; macroglobulinaemia; smouldering multiple myeloma;
D O I
10.1111/j.1365-2141.2007.06873.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Monoclonal gammopathy of undetermined significance (MGUS) is characterized by a serum monoclonal protein < 30 g/l, < 10% plasma cells in the bone marrow, and absence of end-organ damage (CRAB-hypercalcaemia, renal insufficiency, anaemia, or bone lesions). MGUS is present in 3% of persons > 50 years and in 5% > 70 years of age. The risk of progression to multiple myeloma (MM) or a related disorder is 1% per year. Patients with risk factors consisting of an abnormal serum free light chain ratio, non-immunoglobulin G (IgG) MGUS, and an elevated serum M protein >= 15 g/l had a risk of progression at 20 years of 58%, compared with 37% with two risk factors present, 21% with one risk factor present, and 5% when none of the risk factors were present. Smouldering (asymptomatic) multiple myeloma is characterized by having a serum IgG or IgA monoclonal protein of 30 g/l or higher and/or 10% or more plasma cells in the bone marrow but no evidence of end-organ damage. The cumulative probability of progression to active MM or amyloidosis was 51% at 5 years, 66% at 10 years and 73% at 15 years; the median time to progression was 4.8 years.
引用
收藏
页码:730 / 743
页数:14
相关论文
共 86 条
[1]  
ALEXANIAN R, 1975, ARCH INTERN MED, V135, P62, DOI 10.1001/archinte.135.1.62
[2]   Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism - A prospective study [J].
Arnulf, B ;
Bengoufa, D ;
Sarfati, E ;
Toubert, ME ;
Meignin, V ;
Brouet, JC ;
Fermand, JP .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (04) :464-467
[3]   Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement [J].
Asatiani, E ;
Cohen, P ;
Ozdemirli, M ;
Kessler, CM ;
Mavromatis, B ;
Cheson, BD .
AMERICAN JOURNAL OF HEMATOLOGY, 2004, 77 (02) :144-146
[4]  
Avet-Loiseau H, 1999, CANCER RES, V59, P4546
[5]   Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma [J].
Avet-Loiseau, H ;
Li, JY ;
Morineau, N ;
Facon, T ;
Brigaudeau, C ;
Harousseau, JL ;
Grosbois, B ;
Bataille, R .
BLOOD, 1999, 94 (08) :2583-2589
[6]  
Avet-Loiseau H, 1998, CANCER RES, V58, P5640
[7]  
AXELSSON U, 1966, ACTA MED SCAND, V179, P235
[8]  
Badley A D, 1996, Liver Transpl Surg, V2, P375, DOI 10.1002/lt.500020508
[9]   Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: Proposal for a common prognostic scoring system [J].
Baldini, L ;
Goldaniga, M ;
Guffanti, A ;
Broglia, C ;
Cortelazzo, S ;
Rossi, A ;
Morra, E ;
Colombi, M ;
Callea, V ;
Pogliani, E ;
Ilariucci, F ;
Luminari, S ;
Morel, P ;
Merlini, G ;
Gobbi, P .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4662-4668
[10]   Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy [J].
Baldini, L ;
Guffanti, A ;
Cesana, BM ;
Colombi, M ;
Chiorboli, O ;
Damilano, I ;
Maiolo, AT .
BLOOD, 1996, 87 (03) :912-918